The intricate relationship between cannabis use and cognitive function, particularly in high-stakes professions like aviation, poses a significant challenge for regulators and safety bodies worldwide. While the detrimental effects of cannabis on behavior, cognition, and psychomotor performance are generally acknowledged, the exact duration and impact of impairment are far more complex than initially understood, especially with the evolving landscape of cannabis products and their potency.
Early research, such as a comprehensive review by aviation-medicine specialist David Newman for Australia’s Transport Safety Bureau, clearly indicated that complex tasks like piloting an aircraft are highly susceptible to the effects of cannabis. This review highlighted that cannabis’s residual effects could persist for up to 24 hours after consumption. However, the science has become considerably more nuanced as cannabis use has become more prevalent and the strength of cannabis products has intensified across numerous regions.
A pivotal randomised clinical trial conducted in 2022 by Thomas Marcotte at the University of California San Diego, involving 191 regular cannabis users, shed new light on this issue. The study observed that participants who smoked THC demonstrated impaired performance on a simulated driving task. Crucially, the researchers determined that this impairment could not be reliably predicted by the THC content of the cannabis, the users’ prior experience with the substance, or their blood THC concentration. Interestingly, while initial impairment was evident, performance returned to baseline levels, comparable to those who had not consumed the active drug, approximately four and a half hours later. This particular finding holds immense implications for aviation testing protocols.
The challenge for aviation authorities is that a positive test for THC merely indicates its presence, not necessarily when it was consumed or if the individual was impaired at the time of testing. The actual relationship between cannabis use and impairment is influenced by a multitude of factors, including the dose, the method of consumption (e.g., smoking versus edibles), the frequency of use, and an individual’s unique biological response. This complexity distinguishes cannabis from alcohol, where a more straightforward correlation exists between blood alcohol concentrations and impairment. As Marcotte explained, THC rapidly dissipates from the bloodstream after smoking, and there is often a limited to no correlation between blood THC concentrations and actual impairment. Furthermore, in individuals who use cannabis at least occasionally, THC can remain detectable in the blood for days or even weeks, especially in frequent users, long after any acute impairment has subsided.
Studies generally suggest that impairment after smoking cannabis typically lasts between three to five hours. When cannabis is ingested, for instance, through edibles, the duration of impairment extends significantly, usually lasting six to eight hours, and occasionally even longer. In the case of edible consumption, the metabolite 11-hydroxy-THC (11-OH-THC) is often more closely linked with cognitive impairment than THC itself, which might be present in lower concentrations, as noted by Marcotte. Consequently, there is currently no universally accepted, definitive cannabis test that can precisely determine if an individual is too impaired to perform safety-critical tasks like flying.
Responding to these uncertainties, Canada adopted a stringent approach following the legalization of recreational cannabis in 2018. Transport Canada implemented a rule prohibiting flight crews and flight controllers from consuming cannabis for a minimum of 28 days before resuming duty. This rule was specifically designed to mitigate the ambiguities surrounding cannabis impairment and detection. Airlines retain the prerogative to enforce even more stringent regulations.
The American experience further underscores the caution required when interpreting positive drug tests in aviation. A 2026 US National Transportation Safety Board (NTSB) study, which examined pilots killed in US civil aviation accidents between 2018 and 2022, revealed that 52.8% had at least one drug detected, while 27.7% had two or more. THC was identified as the primary contributor to the rise in illicit-drug detections. However, the NTSB emphatically clarified that the study focused on the mere presence of drugs, not on whether the pilots were actually impaired at the time of the incidents. This distinction is paramount in understanding the complexities of drug testing and its implications for aviation safety.
